# IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

> **NCT05814536** · PHASE1 · TERMINATED · sponsor: **AnHeart Therapeutics Inc.** · enrollment: 9 (actual)

## Conditions studied

- Cholangiocarcinoma With IDH1 Mutation
- Solid Tumors With IDH1 Mutation

## Interventions

- **DRUG:** AB-218 capsule

## Key facts

- **NCT ID:** NCT05814536
- **Lead sponsor:** AnHeart Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-06
- **Primary completion:** 2024-08-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Sponsor adjusted the study strategy
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05814536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05814536, "IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05814536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*